This last generation FDA Hep C approval will not. be. enough. to make any difference -- overall, for Schering.
Just as the Foradil market is small, so too, is this -- and short-lived. In a year or so, Vertex will literally obsolete this whole pegalated line of therapy, altogether. Vertex's Teleprevir will crush Schering's Boceprevir.
And no one will accept the current low success rates (especially amount non-naive patients!), and daunting side-effects this current generation of Hep C treatments cause.